With oral dosing of edoxaban , co-administration of various P-gp inhibitors significantly increased edoxaban bioavailability and decreased volume of distribution ( V @ ) , resulting in a predicted increase of @-@ % in area under the curve ( AUC ) and @-@ % in C max .